Skip to content
Poster

Hepatoprotective effects of the oral fatty acid synthase inhibitor TVB-3664 in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Background & Aim:

Fatty acid synthase (FASN) inhibitors is a promising drug class for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Accordingly, the oral FASN inhibitor denifanstat (TVB-2640) has recently been reported to improve NAFLD Activity Score (NAS) and fibrosis stage in a phase 2b clinical trial (FASCINATE-2) in MASH patients. The present study aimed to investigate the effect of TVB-3664, an oral FASN inhibitor, on metabolic, biochemical and histological endpoints in the translational Gubra Amylin NASH (GAN) dietinduced obese and biopsy-confirmed mouse model of MASH with liver fibrosis.

Subjects
GAN DIO-MASH mouseMouseBody compositionBlood biochemistryMetabolic dysfunction-associated steatohepatitisFatty acid synthaseHistopathology scoreImage analysisImmunohistochemistry (IHC)Liver biopsyLiver morphometryRNA sequencingTVB-3664

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top